iNot medical advice. We don’t recommend any dose. Every dose below is a quote from the person named, describing their views or their own use. Semaglutide (Ozempic, Wegovy, Rybelsus) is a prescription medicine in the EU, UK and US. Only a prescriber can decide whether and how you should use it.
5 statements from 3 people. Each one is word for word: we add punctuation only and mark cuts with […]. The chips repeat the exact words used.
“Now what I'm doing right now is the sema […] so far I'm at .25 and I have not, I'll probably have to do an update video, but um didn't notice a whole lot today yet, but it is early still”
Context: Own use, in 2021. Just before, he explains that the newly approved weight-loss pen is 2.4 mg a week and that Ozempic for diabetes is dosed from 0.25; he does not repeat the unit after “.25”.
“The one that's just been FDA approved of the 2.4 milligram dose, which works well even at like 0.5 to 1 milligrams, so even as low as 0.25 some people don't even need to titrate higher than that”
Context: About semaglutide (“the one that's just been FDA approved”), describing what he has seen, not a recommendation.
“[…] So you cannot actually, even if your weekly dose is 2.4 milligrams, it would be more ideal probably to administer on a every three day cadence, every two day cadence, or ideally on like an everyday cadence potentially, if you wanted to attenuate some of these side effects”
Context: He is criticising fixed-dose pharmacy pens, which make it hard to split a weekly dose. Hedged (“probably”, “potentially”).
“The only thing I will note is that beyond a weekly dose of 0.3 mg, I don’t experience additional side effects but I start feeling woozy. You’ll definitely have to experiment with the dosage to see what’s best for you. HOW I USE SEMAGLUTIDE: 0.25 mg injected subcutaneously once a week (preferably on a day you are eating and training on), gradually increasing the dose every 4 weeks up to a maximum of 2.4 mg or until you see the appetite-suppressing effects you want.”
Context: Own use in 2022. Semaglutide is a prescription medicine; the licensed products have their own dose schedules.
“It's probably safer to microdose retatrutide or the other GLP-1 receptor agonists, maybe three times weekly, Monday, Wednesday, Friday, at a low and effective dose, just enough to blunt your appetite, promote satiation, and take away the food noise when you're undergoing a cutting phase”
Context: Said in a video about retatrutide and applied by him to “the other GLP-1 receptor agonists”; he does not give a semaglutide-specific dose. Clip published on VigorousClips; the same passage is in his full video of 31 Mar 2025.
4 statements from 2 people about risks and how strong the evidence is.
“And if you respond poorly, like, you're going to be in for a rough week, so obviously this is where titration from the lowest effective dose makes sense”
Context: Comparing once-weekly semaglutide with daily liraglutide.
“[…] that is cranking up resting heart rate, like, I don't really know, but it is uh concerning and should at least be noted and considered before you just jump on this […]”
Context: Discussing reported increases in resting heart rate with GLP-1 agonists; he is openly speculating about the mechanism. The cut removes a profanity.
“First, I’m really honest about the fact that side effects with GLP-1 medications are common. And I explain what the most common side effects are: nausea, vomiting, diarrhea, and constipation […]. Symptoms are usually mild to moderate. For most patients, they improve over time as their bodies adjust to the medication.”
Context: From his article on GLP-1 medicines including semaglutide, describing what he tells his own patients. A reference marker is replaced by […].
“In other words, adding exercise cut the lean mass loss in half. This is why adding resistance training (and getting adequate protein) are strongly recommended when undertaking any weight-loss program.”
Context: His conclusion after comparing lean-mass loss on semaglutide with diet-only weight loss.
Context, not a dosing guide. These are the regimens used in large randomised trials under medical supervision. They describe what was tested, not a recommendation.
| Study | Studied in | What the study used | What it found |
|---|---|---|---|
| STEP 1: Wilding et al., 2021, N Engl J MedPubMed 33567185 | 1,961 adults with obesity or overweight, no diabetes | 2.4 mg subcutaneously weekly for 68 weeks | Body weight −14.9% vs −2.4% with placebo |
| SELECT: Lincoff et al., 2023, N Engl J MedPubMed 37952131 | 17,604 adults with cardiovascular disease and overweight, no diabetes | 2.4 mg weekly | Major cardiovascular events HR 0.80; stopped for adverse events 16.6% vs 8.2% |
| SUSTAIN-6: Marso et al., 2016, N Engl J MedPubMed 27633186 | 3,297 adults with type 2 diabetes | 0.5 or 1.0 mg weekly for 104 weeks | Fewer major cardiovascular events vs placebo; more retinopathy complications |
Yes. It is approved in the EU, UK and US for type 2 diabetes (Ozempic, Rybelsus) and weight management (Wegovy).
Not in the approval trials, which used once-weekly injections. The experts quoted above present them as their own views.
Gastrointestinal effects are the most common in the trials. See the quotes from Dr Stanfield and Derek above.
We do not give dosing advice. Your prescriber and the product information decide dosing.
Word-for-word statements about how semaglutide is used, including splitting and titrating doses, each with a link to the source. The large trials behind its approval are listed separately as context.
Last reviewed 11 Oct 2026 · Compiled by the Peptide Dosing editorial team · How we check quotes